Sugi Predict

Sugi Predict / Compounds / SCHEMBL25272811

SCHEMBL25272811

SCHEMBL25272811

COc1nc(Cl)cc(C)c1C=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.36
▸ LMNA P02545 2/20 0.36
▸ CYP2C19 P33261 3/20 0.34
▸ CYP3A4 P08684 2/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ KDM4E B2RXH2 3/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ CCR4 P51679 4/20 0.33
▸ MAPT P10636 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ MPI P34949 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ RECQL P46063 2/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23726022 0.84 ALDH1A1 (0.34) ALDH1A1LMNAKDM4ESMN1; SMN2GAA
SCHEMBL2674287 0.83 CYP1A2 (0.44) ALDH1A1LMNACYP2C19CYP3A4CYP1A2
SCHEMBL615593 0.81 ALDH1A1 (0.33) ALDH1A1LMNASMN1; SMN2GAAHPGD
SCHEMBL23724851 0.81 CCR4 (0.39) ALDH1A1LMNASMN1; SMN2GAAHPGD
SCHEMBL29993082 0.80 CYP3A4 (0.34) ALDH1A1CYP2C19CYP3A4CYP1A2CYP2D6
SCHEMBL29993460 0.80 TRPV4 (0.32) LMNACYP2C19CYP3A4CYP1A2CYP2D6
SCHEMBL24773241 0.80 CYP3A4 (0.34) ALDH1A1CYP2C19CYP3A4CYP1A2CYP2D6
SCHEMBL24773239 0.80 TRPV4 (0.32) LMNACYP2C19CYP3A4CYP1A2CYP2D6
SCHEMBL5372841 0.80 POLB (0.51) ALDH1A1LMNACYP2C19CYP1A2KDM4E
SCHEMBL615179 0.77 POLB (0.32) CYP2C19CYP1A2POLBRECQLCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12428427-B2 Methods and compositions for targeting PD-L1 ALIGOS THERAPEUTICS, INC. (US) 2025-09-30 — — US disclosed
US-20240277706-A1 METHODS AND COMPOSTITIONS FOR TARGETING PD-L1 ALIGOS THERAPEUTICS, INC. 2024-08-22 — — US disclosed
US-11760761-B2 Methods and compositions for targeting PD-L1 ALIGOS THERAPEUTICS, INC. (US) 2023-09-19 — — US disclosed
US-11760761-B2 Methods and compositions for targeting PD-L1 ALIGOS THERAPEUTICS, INC. (US) 2023-09-19 — — US disclosed
US-20230192713-A1 METHODS AND COMPOSITIONS FOR TARGETING PD-L1 ALIGOS THERAPEUTICS, INC. 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240277706-A1 METHODS AND COMPOSTITIONS FOR TARGETING PD-L1 CD274, PDCD1, PDCD1LG2 ALDH1A1 950/4885LMNA 1997/4885CYP2C19 3346/4885
US-20230192713-A1 METHODS AND COMPOSITIONS FOR TARGETING PD-L1 CD274, PDCD1LG2, PDCD1 ALDH1A1 301/4885LMNA 2102/4885CYP2C19 3260/4885
US-11760761-B2 Methods and compositions for targeting PD-L1 CD274, PDCD1LG2, PDCD1 ALDH1A1 301/4885LMNA 2102/4885CYP2C19 3260/4885
US-12428427-B2 Methods and compositions for targeting PD-L1 CD274, PDCD1LG2, PDCD1 ALDH1A1 301/4885LMNA 2102/4885CYP2C19 3260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.